Equities research analysts expect that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will announce sales of $107.94 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $103.67 million to $110.63 million. Supernus Pharmaceuticals reported sales of $88.44 million during the same quarter last year, which suggests a positive year-over-year growth rate of 22%. The company is expected to issue its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $400.89 million for the current fiscal year, with estimates ranging from $396.63 million to $403.60 million. For the next year, analysts forecast that the firm will report sales of $464.92 million, with estimates ranging from $450.92 million to $472.58 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The firm had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period last year, the business posted $0.29 EPS.
Shares of SUPN stock traded up $0.04 on Friday, reaching $42.82. The stock had a trading volume of 226,504 shares, compared to its average volume of 703,397. The company has a market cap of $2.24 billion, a P/E ratio of 33.98 and a beta of 0.92. Supernus Pharmaceuticals has a 1 year low of $34.90 and a 1 year high of $61.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Supernus Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc. now owns 5,116,478 shares of the specialty pharmaceutical company’s stock valued at $257,614,000 after acquiring an additional 160,765 shares during the period. Legal & General Group Plc raised its holdings in Supernus Pharmaceuticals by 8.4% during the third quarter. Legal & General Group Plc now owns 120,214 shares of the specialty pharmaceutical company’s stock valued at $6,039,000 after acquiring an additional 9,318 shares during the period. Teachers Advisors LLC raised its holdings in Supernus Pharmaceuticals by 2.5% during the third quarter. Teachers Advisors LLC now owns 97,941 shares of the specialty pharmaceutical company’s stock valued at $4,931,000 after acquiring an additional 2,352 shares during the period. Glenmede Trust Co. NA raised its holdings in Supernus Pharmaceuticals by 52.2% during the third quarter. Glenmede Trust Co. NA now owns 993,483 shares of the specialty pharmaceutical company’s stock valued at $50,020,000 after acquiring an additional 340,677 shares during the period. Finally, Macquarie Group Ltd. bought a new stake in Supernus Pharmaceuticals during the third quarter valued at about $28,617,000. 97.83% of the stock is currently owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
See Also: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.